ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2155

The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation

Sara Remuzgo-Martínez1, Diana Prieto-Peña 2, Mónica Calderón-Goercke 2, Victor Manuel Mora Cuesta 3, David Iturbe Fernández 1, Sonia M. Fernández Rozas 3, Jose Manuel Cifrian Martínez 3 and Miguel Angel González-Gay 4, 1Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, 2Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, 3Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, 4Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: autoimmune diseases, epidemiology and lung transplantation, interstitial lung disease

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of morbidity and mortality [2].  In the present study, we aimed to determine the frequency of ILD associated with AD (AD-ILD) among patients sent for assessment to a clinic of lung transplantation from a referral center. The different types of AD-ILD were described.

Methods: Clinical records of patients seen at the ILD clinic of Hospital Universitario Marqués de Valdecilla, Santander, Spain between May 2016 and May 2019 were reviewed. A diagnosis of ILD was made by the pneumologists based on clinical and radiological findings and pulmonary function test abnormalities. A definitive histological confirmation by transbronchial biopsy, surgical lung biopsy or cryobiopsy was performed according to the pneumologist consideration. All patients with ILD seen at the clinic were also assessed by an experienced rheumatologist to exclude the presence of an underlying AD.

Results: During the period of assessment, 384 patients were diagnosed with ILD in this referral clinic (Table). The diagnosis of ILD was histologically confirmed in 208 (54.2%) patients. Among the 384 ILD patients, 129 were diagnosed as having idiopathic pulmonary fibrosis (33.6%). Other frequent conditions unrelated to AD were chronic hypersensitivity pneumonitis (n= 40; 10.4%), non-classifiable interstitial pneumonia (n= 44; 11.5%) and non-specific interstitial pneumonia (n=20; 5.2%). Ninety-one (23.7%) of the ILD patients fulfilled definitions for AD. Most cases with AD-ILD were due to rheumatoid arthritis (n= 25/91; 27.5%); systemic sclerosis (n=24/91; 26.4%), anti-synthetase syndrome (n= 16/91; 17.6%) and Sjogren’s syndrome (n= 6/91; 6.6%). Interestingly, 15 of 91 patients with AD-ILD (16.5%) were diagnosed as having an interstitial pneumonia with autoimmune features. Other AD associated with ILD are shown in Table. The predominant radiological pattern in patients with rheumatoid arthritis was usual interstitial pneumonia. In contrast, a predominant non-specific interstitial pneumonia pattern was found in the remaining patients with AD. 

Conclusion: Almost a quarter of patients with ILD seen at a referral clinic center have an underlying AD. Close assessment of patients with ILD by rheumatologists is of main importance to identify AD in patients with ILD.

References:

[1] Cottin et al. Eur Respir Rev 2018;27:180076; [2] Antoniou et al. Eur Respir J 2009;33:882-896.

Acknowledgments:

SR-M is supported by funds of the RETICS Program RD16/0012/0009 (Instituto de Salud Carlos III (ISCIII), co-funded by the European Regional Development Fund (ERDF).


Disclosure: S. Remuzgo-Martínez, None; D. Prieto-Peña, None; M. Calderón-Goercke, None; V. Mora Cuesta, None; D. Iturbe Fernández, None; S. Fernández Rozas, None; J. Cifrian Martínez, None; M. González-Gay, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, Celgene, 5, 8, Eli Lilly, 2, 5, EliLilly, 2, 5, Jansen, 2, Janssen, 2, MSD, 2, 5, 8, Novartis, 2, 5, Pfizer, 5, 8, Roche, 2, 5, 8, Sanofi, 2, 5, 8, Sobi, 5, 8.

To cite this abstract in AMA style:

Remuzgo-Martínez S, Prieto-Peña D, Calderón-Goercke M, Mora Cuesta V, Iturbe Fernández D, Fernández Rozas S, Cifrian Martínez J, González-Gay M. The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-spectrum-of-interstitial-lung-disease-associated-with-autoimmune-diseases-data-of-a-3-year-prospective-study-from-a-referral-center-of-lung-transplantation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-spectrum-of-interstitial-lung-disease-associated-with-autoimmune-diseases-data-of-a-3-year-prospective-study-from-a-referral-center-of-lung-transplantation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology